top of page

Modeling-based response-guided therapy for chronic hepatitis C under glecaprevir/pibrentasvir may identify patients for ultra-short treatment duration

Swikriti Dasgupta, Michio Imamura, Evan Gorstein, Takashi Nakahara, Masataka Tsuge, Alexander Churkin, David Yardeni, Ohad Etzion, Susan L. Uprichard, Danny Barash, Scott J. Cotler, Harel Dahari, Kazuaki Chayama


April 2020


We recently showed in a proof-of-concept study that real-time modeling-based response-guided therapy (RGT) can shorten hepatitis C virus (HCV) treatment duration with sofosbuvir/velpatasvir, elbasvir/grazoprevir and sofosbuvir/ledipasvir without compromising efficacy, confirming our retrospective modeling reports in more than 200 patients. However, retrospective modeling under pibrentasvir/glecaprevir (P/G) has yet to be evaluated. In the current study modeling HCV kinetics in 44 cirrhotic and non-cirrhotic patients predicts that P/G treatment might have been reduced to 4, 6 and 7 weeks in 16%, 34% and 14% of patients, respectively. These results support the further evaluation of a modeling-based RGT approach under P/G therapy.

bottom of page